E-LIB Suche - Ergebnisse für: Grosicki, S.

1

ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN..:

Shadman, M. ; Munir, T. ; Roback, T....
Hematological Oncology. 41 (2023) S2 - p. 235-238 , 2023

Link: https://doi.org/10.1002/..

2

LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIM..:

Carlo‐Stella, C. ; Kwiatek, M. ; Chung, M....
Hematological Oncology. 41 (2023) S2 - p. 850-851 , 2023

Link: https://doi.org/10.1002/..

3

P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUD..:

Vorobyev, V. ; Yoon, D. H. ; Kaźmierczak, M....
HemaSphere. 6 (2022) - p. 1013-1014 , 2022

Link: https://doi.org/10.1097/..

4

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOU..:

Vannucchi, A. ; Mesa, R. ; Gerds, A....
HemaSphere. 6 (2022) - p. 940-941 , 2022

Link: https://doi.org/10.1097/..

5

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MM..:

Verstovsek, S. ; Vannucchi, A. ; Gerds, A....
HemaSphere. 6 (2022) - p. 96-97 , 2022

Link: https://doi.org/10.1097/..

6

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN ..:

Nooka, A. ; Lonial, S. ; Grosicki, S....
HemaSphere. 6 (2022) - p. 829-830 , 2022

Link: https://doi.org/10.1097/..

7

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BL..:

Harrison, C. ; Rampal, R. K. ; Gupta, V....
HemaSphere. 6 (2022) - p. 920-921 , 2022

Link: https://doi.org/10.1097/..

8

FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRON..:

Coutre, S. E. ; Barr, P. M. ; Owen, C....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZO..:

Quach, H. ; Nooka, A. ; Samoylova, O....
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 253-254 , 2020

Link: https://doi.org/10.1016/..

10

FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT O..:

Tedeschi, A. ; Burger, J. ; Barr, P.M....
Hematological Oncology. 37 (2019) S2 - p. 103-104 , 2019

Link: https://doi.org/10.1002/..

11

Updated results from the phase 3 HELIOS study of ibrutinib,..:

Fraser, G. ; Cramer, P. ; Demirkan, F....
Leukemia. 33 (2018) 4 - p. 969-980 , 2018

Link: https://doi.org/10.1038/..

12

REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEAL..:

Thieblemont, C. ; Casasnovas, R. ; Mounier, N....
Hematological Oncology. 35 (2017) S2 - p. 102-103 , 2017

Link: https://doi.org/10.1002/..

13

Limiting current technique in the research of mass/heat tra..:

Wilk, J ; Grosicki, S
Journal of Physics: Conference Series. 745 (2016) - p. 032084 , 2016

Link: https://doi.org/10.1088/..

14

A multicenter, open, noncomparative, phase II study of the ..:

Wrzesień-Kuś, A. ; Robak, T. ; Wierzbowska, A....
Annals of Hematology. 84 (2005) 9 - p. 557-564 , 2005

Link: https://doi.org/10.1007/..

15

Addition of Cladribine to Induction/Consolidation Regimen D..:

Holowiecki, J. ; Grosicki, S. ; Sadus-Wojciechowska, M....
Transplantation Proceedings. 37 (2005) 10 - p. 4482-4487 , 2005

Link: https://doi.org/10.1016/..